QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$36.18 USD
-2.78 (-7.14%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $36.21 +0.03 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.18 USD
-2.78 (-7.14%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $36.21 +0.03 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Zacks News
QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.
QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 174.19% and 12.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's strong product portfolio raises optimism about the stock.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's strong product portfolio raises optimism about the stock.
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod
by Zacks Equity Research
QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.
QuidelOrtho (QDEL) Up 3.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.
QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 66.67% and 3.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Strength Seen in National Vision (EYE): Can Its 7.2% Jump Turn into More Strength?
by Zacks Equity Research
National Vision (EYE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.
Here's What Key Metrics Tell Us About QuidelOrtho (QDEL) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for QuidelOrtho (QDEL) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 2.33% and 1.96%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling QuidelOrtho (QDEL) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for QuidelOrtho (QDEL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
BioLife Solutions (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -19.05% and 2.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing
by Zacks Equity Research
QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
by Zacks Equity Research
QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.
QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.
QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall
by Zacks Equity Research
Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.
QuidelOrtho (QDEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for QuidelOrtho (QDEL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
QuidelOrtho (QDEL) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.08% and 6.97%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?